

**Antibiotic % Susceptibility  
Calgary Zone Candida from Sterile Sites  
May -December 2023<sup>a</sup>**

Data derived from routine susceptibility tests performed  
by Alberta Precision Laboratories

|                  | <b>N</b>  | <b>Fluconazole</b> | <b>Voriconazole</b> | <b>Micafungin</b> | <b>Amphotericin B</b> |
|------------------|-----------|--------------------|---------------------|-------------------|-----------------------|
| Candida albicans | <b>69</b> | 97 <sup>b</sup>    | 93                  | 100               | 100                   |
| Candida glabrata | <b>42</b> | 98 <sup>c</sup>    |                     | 100               | 100                   |

<sup>a</sup>Due to launch of Connect Care in May 2023, data from Jan-April not included.

<sup>b</sup>Susceptible interpretation based on drug dosage 6mg/kg/day, appropriate for age > 1 month and creatinine clearance > 50 mL/min (e.g. 400mg/day for 70kg person).

<sup>c</sup> For isolates which test susceptible, susceptibility depends on achieving the maximum possible blood level. Doses higher than the standard dosing amount (e.g. 12 mg/kg/day = 800mg/d for 70kg person) may be needed in adults with normal renal function and body habitus.

Note: Percent susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism recovered from a given patient during the time period analyzed.



# ALBERTA PRECISION LABORATORIES

Leaders in Laboratory Medicine

## Antifungal % Susceptibility Patterns: Candida - Sterile

Calgary zone

January - December 2022

Data derived from routine susceptibility tests performed by Alberta Precision Laboratories

| N | Fluconazole<br>6 mg/kg/day <sup>a</sup> | Fluconazole<br>12 mg/kg/day <sup>a</sup> | Voriconazole | Micafungin | Amphotericin B |
|---|---|--|--------------|------------|----------------|
|---|---|--|--------------|------------|----------------|

| Yeast            |    |    |    |                 |     |              |
|------------------|----|----|----|-----------------|-----|--------------|
| Candida albicans | 55 | 98 |    | 98              | 100 | 98           |
| Candida glabrata | 31 |    | 94 | 77 <sup>b</sup> | 100 | <sup>c</sup> |

<sup>a</sup> Susceptible interpretation based on drug dosage appropriate for age > 1 month and creatinine clearance > 50 mL/min

<sup>b</sup> % likely susceptible based on the minimum inhibitory concentration distribution of isolates without acquired mechanisms of resistance (i.e. wild type)

<sup>c</sup> data currently under review

**Note:** Percent susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism recovered from a given patient during the time period analyzed.